Navigation Links
Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
Date:4/22/2008

STOCKHOLM, April 22 /PRNewswire/ --

- Summary: Using Protein Tomography(TM), Sidec Investigated in Collaboration With Genmab the Molecular Mode of Action of Humax- EGFr (Zalutumumab). In This Study Sidec Showed That EGFr is Flexible and That Zalutumumab Locks the EGFr Into a Very Compact Inactive Conformation Thereby Inhibiting Cell Signaling and Cancer Cell Growth.

Sidec AB announced today that together with Genmab the molecular mode of action of HuMax-EGFr (zalutumumab) has been determined. It was shown that zalutumumab locks the epidermal growth factor receptor (EGFr) molecules into a compact, inactive conformation. Flexibility is crucial to the role of the EGFr in signaling, and this study, done with Sidec's proprietary methodology Protein Tomography(TM), has played a central role in the understanding of the inhibition of individual EGFr molecules. Moreover, Sidec's unique technology confirmed that HuMax-EGFr binds bivalently to the EGFr. Prevention of the receptor dimerization as well as locking the EGFr molecules in the inactive form both contribute to the inhibition of signaling and cancer cell growth.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

This data will be demonstrated on Sidec's First Protein Tomography Symposium at the fourth annual PEGS Summit 28 April - 2 May at the Intercontinental Hotel in Boston.

With Protein Tomography it is possible to study the molecular mode of action of individual molecules in situ and in vitro. The unique biological information obtained can also be used to prioritize the most promising monoclonal antibodies/projects and to locate the antibody binding epitope.

"These results clearly show the importance of understanding the molecular mode of action and to capture the flexibility of a receptor when developing therapeutic antibodies. Today this can only be done with Protein Tomography(TM) and we are proud to have contributed to Genmab's new insight to HuMax-EGFr mechanism of action." says Hans Johansson CEO at Sidec AB.

The new findings will be published in the journal Proceedings of the National Academy of Science of the United States of America (PNAS) in the edition published on April 21, 2008

About Sidec

Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaboration research projects to the biopharmaceutical industry and reveals unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope.

For more information, please contact:

Mr.Hans Johansson, CEO

Phone: +46(0)8-4777-602

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
5. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
6. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
9. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
10. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
11. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):